PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors Prior treatment with methioninase shown to sensitize certain solid tumor types to asparaginase-based treatment New patent granting adding to portfolio of 310 granted patents in 16 patent
View HTML
Toggle Summary ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
Conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30pm CET          Progress towards  seeking   approval  of  eryaspase  for the   treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase ; Fast   Track designation granted; submission of BLA
View HTML
Toggle Summary ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France) , November 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue 10)
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Date
View HTML
Toggle Summary ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer Management to host Conference Call on Monday, October 25, at 8:30am EDT/ 2:30pm CEST          T he trial did not meet its primary endpoint of overall survival The prespecified
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2021.
               Monthly information related to total number of voting rights and shares composing the share capital – September 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces M aximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose - l imiting t oxicity (DLT) reported in first two dose cohorts, leading to de c laration of the m aximum t olerated d ose (MTD) at 100 U/kg Encouraging
View HTML
Toggle Summary ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech Cambridge, MA (U.S.) and Lyon (France), September 28 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Announces the Availability of its Half-Year Financial Report 2021
ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1 Lyon (France) a nd Cambridge, MA (U.S.), Septembre 2 2 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Top